MGX

Metagenomi is a precision genetic medicines company developing a proprietary portfolio of next-generation gene editing tools. By leveraging a vast database of metagenomic data, the company identifies and optimizes novel CRISPR-based systems, including base editors and RNA-mediated integration systems. Their platform aims to overcome the limitations of first-generation gene editing technologies, such as size constraints and PAM requirements, to treat a wide range of genetic diseases. The company's pipeline includes programs for metabolic, cardiovascular, and neuromuscular disorders, supported by strategic collaborations with industry leaders like Ionis Pharmaceuticals.